 |
ImaginAb has several important companion diagnostic collaborations with Astellas and their US subsidiary, Agensys. Read about it here.
|
 |
ImaginAb has both in-licensing agreements and clinical collaboration with City of Hope, including joint NCI grants.
|
 |
Discovered by Prof. Neil Bander at Cornell Weil, ImaginAb’s anti-PSMA imaging agent is based on the superb huJ591 antibody (BZL).
|
 |
DNS is an innovative Japanese engineering firm with a commitment to excellence in radiochemistry and synthesis equipment.
|
 |
Our collaboration with Eurogentec explores the possibility of new expression systems for ImaginAb’s minibody technology.
|
 |
Fox Chase researchers have pioneered engineered antibody technologies and molecular imaging.
|
 |
ImaginAb has partnered with Lundbeck around a novel central nervous system target. Read more about it here.
|
 |
Our collaboration with Macrogenics around CD3 and B7H3 aims to accelerate clinical development of immune-directed imaging agents in cancer and autoimmune disease.
|
 |
MSKCC’s world-leading nuclear medicine team is a key collaborator for radiochemistry process development, including 89Zr.
|
 |
We are grateful to the NCI for SBIR/STTR funding and their leadership in personalized medicine.
|
 |
We are pleased to have partnered with Oxford Biomedica to develop anti-5T4 imaging for unmet needs in oncology.
|
 |
SRP is a regional partner for ImaginAb’s Singapore subsidiary for both custom synthesis and cGMP process development.
|
 |
UCLA is important as a scientific, intellectual property and clinical collaboration site for ImaginAb.
|
 |
Under the clinical leadership of Professor Richard Baum, ZentralKlinik is a world-leader in advanced molecular imaging and radioimmunotherapy.
|
